Global incidence and prevalence of nonalcoholic fatty liver disease

키워드

참고문헌 (65)

1. Cheemerla S, "Global epidemiology of chronic liver disease", Clin Liver Dis(Hoboken), 17, pp.365~370 (2021)
2. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
3. Riazi K, "The prevalence and incidence of NAFLD worldwide : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 7, pp.851~861 (2022)
4. GBD 2015 Obesity Collaborators, "Health effects of overweight and obesity in 195 countries over 25 years", N Engl J Med, 377, pp.13~27 (2017)
5. Stefan N, "A global view of the interplay between nonalcoholic fatty liver disease and diabetes", Lancet Diabetes Endocrinol, 10, pp.284~296 (2022)
6. Tan DJH, "Global burden of liver cancer in males and females : changing etiological basis and the growing contribution of NASH", Hepatology (2022)[DOI]
7. Huang DQ, "Changing global epidemiology of liver cancer from 2010 to 2019 : NASH is the fastest growing cause of liver cancer", Cell Metab, 34, pp.969~977 (2022)
8. Younossi ZM, "Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States", Clin Gastroenterol Hepatol, 19, pp.580~589 (2021)
9. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
10. Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
11. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
12. Le MH, "2019 Global NAFLD prevalence : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 20, pp.2809~2817 (2022)
13. Wu Y, "The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product : a meta-analysis", Hepatol Int, 14, pp.259~269 (2020)
14. Zhou F, "Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018 : a systematic review and meta-analysis", Hepatology, 70, pp.1119~1133 (2019)
15. Im HJ, "Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea", Clin Res Hepatol Gastroenterol, 45, pp.101526~ (2021)
16. Jaejun Lee, "Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population- based cross-sectional study", Clinical and Molecular Hepatology, 28(2), pp.196~206 (2022), 대한간학회[DOI]
17. Seung Ha Park, "Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017", Clinical and Molecular Hepatology, 26(2), pp.209~215 (2020), 대한간학회[DOI]
18. Ito T, "The epidemiology of NAFLD and lean NAFLD in Japan : a metaanalysis with individual and forecasting analysis, 1995-2040", Hepatol Int, 15, pp.366~379 (2021)
19. "Obesity update 2017"[URL]
20. "IDF Diabetes Atlas Ninth edition 2019"[URL]
21. Ikeda N, "What has made the population of Japan healthy?", Lancet, 378, pp.1094~1105 (2011)
22. "Global Burden of Disease Study 2019 (GBD 2019) results"[URL]
23. Jeong-Ju Yoo, "Recent research trends and updates on nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 25(1), pp.1~11 (2019), 대한간학회
24. Fan JG, "New trends on obesity and NAFLD in Asia", J Hepatol, 67, pp.862~873 (2017)
25. Nazare JA, "Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile : the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship With Cardiometabolic Risk", IntraAbdominal Adiposity, 2012, pp.96, 714~726
26. Hanlon CL, "Nonalcoholic fatty liver disease: the role of visceral adipose tissue", Clin Liver Dis(Hoboken), 19, pp.106~110 (2022)
27. Yoon KH, "Epidemic obesity and type 2 diabetes in Asia", Lancet, 368, pp.1681~1688 (2006)
28. Huxley R, "Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension", Obes Rev, 9(Suppl 1), pp.53~61 (2008)
29. Chan JC, "Diabetes in Asia : epidemiology, risk factors, and pathophysiology", JAMA, 301, pp.2129~2140 (2009)
30. Hagström H, "Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease : a long-term followup study", Hepatol Commun, 2, pp.48~57 (2018)
31. Cholongitas E, "Epidemiology of nonalcoholic fatty liver disease in Europe : a systematic review and meta-analysis", Ann Gastroenterol, 34, pp.404~414 (2021)
32. Nabi O, "Prevalence and risk factors of nonalcoholic fatty liver disease and advanced fibrosis in general population : the French Nationwide NASH-CO Study", Gastroenterology, 159, pp.791~793 (2020)
33. Bikbov MM, "Prevalence of non-alcoholic fatty liver disease in the Russian Ural Eye and Medical Study and the Ural Very Old Study", Sci Rep, 12, pp.7842~ (2022)
34. Browning JD, "Prevalence of hepatic steatosis in an urban population in the United States : impact of ethnicity", Hepatology, 40, pp.1387~1395 (2004)
35. Lazo M, "Prevalence of nonalcoholic fatty liver disease in the United States : the Third National Health and Nutrition Examination Survey, 1988-1994", Am J Epidemiol, 178, pp.38~45 (2013)
36. Kim D, "Race", ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016, 2019, pp.13, 205~213
37. Zhang X, "Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults : results from NHANES 2017-2018", PLoS One, 16, pp.e0252164~ (2021)
38. Sherif ZA, "Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations", Dig Dis Sci, 61, pp.1214~1225 (2016)
39. Arshad T, "Epidemiology of nonalcoholic fatty liver disease in North America", Curr Pharm Des, 26, pp.993~997 (2020)
40. Romeo S, "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
41. Wagenknecht LE, "Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort : the Insulin Resistance Atherosclerosis Family Study", Liver Int, 31, pp.412~416 (2011)
42. Guerrero R, "Ethnic differences in hepatic steatosis : an insulin resistance paradox?", Hepatology, 49, pp.791~801 (2009)
43. Rojas YAO, "Nonalcoholic fatty liver disease prevalence in Latin America : a systematic review and meta-analysis", Ann Hepatol, 27, pp.100706~ (2022)
44. Pinto Marques Souza de Oliveira C, "Nonalcoholic fatty liver disease risk factors in Latin American populations: current scenario and perspectives", Clin Liver Dis(Hoboken), 13, pp.39~42 (2019)
45. Arrese M, "High prevalence of PNPLA3 rs738409(I148M)polymorphism in Chilean latino population and its association to nonalcoholic fatty liver disease risk and histological disease severity", Hepatology, 62(Suppl 1), pp.1285A~ (2015)
46. Pontoriero AC, "Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations", BMC Genet, 16, pp.93~ (2015)
47. Chinchilla-López P, "More evidence for the genetic susceptibility of Mexican population to nonalcoholic fatty liver disease through PNPLA3", Ann Hepatol, 17, pp.250~255 (2018)
48. Patel SA, "Obesity and its relation with diabetes and hypertension : a cross-sectional study across 4 geographical regions", Glob Heart, 11, pp.71~79 (2016)
49. Gallardo-Rincón H, "Review : type 2 diabetes in Latin America and the Caribbean : regional and country comparison on prevalence, trends, costs and expanded prevention", Prim Care Diabetes, 15, pp.352~359 (2021)
50. Guthold R, "Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1·9 million participants", Lancet Glob Health, 6, pp.e1077~e1086 (2018)
51. Younossi Z, "Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
52. Spearman CW, "Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa", Lancet Gastroenterol Hepatol, 6, pp.1036~1046 (2021)
53. Ge X, "Prevalence trends in nonalcoholic fatty liver disease at the global, regional and national levels, 1990-2017 : a population-based observational study", BMJ Open, 10, pp.e036663~ (2020)
54. Roberts SK, "Prevalence of non-alcoholic fatty liver disease in regional Victoria : a prospective population-based study", Med J Aust, 215, pp.77~82 (2021)
55. Farrell AM, "A problem of proportions : estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study", Sci Rep, 12, pp.1956~ (2022)
56. Mahady SE, "Burden of non-alcoholic fatty liver disease in Australia", J Gastroenterol Hepatol, 33(Suppl 1), pp.1~11 (2018)
57. Michael H. Le, "Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach", Clinical and Molecular Hepatology, 28(4), pp.841~850 (2022), 대한간학회
58. Estes C, "Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030", J Hepatol, 69, pp.896~904 (2018)
59. Estes C, "Modelling NAFLD disease burden in four Asian regions-2019-2030", Aliment Pharmacol Ther, 51, pp.801~811 (2020)
60. Alswat K, "Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017-2030", Saudi J Gastroenterol, 24, pp.211~219 (2018)
61. Estes C, "Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease", Hepatology, 67, pp.123~133 (2018)
62. Swain MG, "Burden of nonalcoholic fatty liver disease in Canada, 2019-2030 : a modelling study", CMAJ Open, 8, pp.E429~E436 (2020)
63. Adams LA, "Nonalcoholic fatty liver disease burden : Australia, 2019-2030", J Gastroenterol Hepatol, 35, pp.1628~1635 (2020)
64. Lazarus JV, "Advancing the global public health agenda for NAFLD : a consensus statement", Nat Rev Gastroenterol Hepatol, 19, pp.60~78 (2022)
65. Karlsen TH, "The EASL-Lancet Liver Commission : protecting the next generation of Europeans against liver disease complications and premature mortality", Lancet, 399, pp.61~116 (2022)

관련 논문AI추천